Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety of Galantamine in Alzheimer's Disease
NCT00309725Phase 3Completed
- Sponsor
- Johnson & Johnson
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Galantamine with Placebo (2 arms). Primary endpoints: Hourly mean heart rates at Week 6 and Hourly mean PR intervals at Week 6. Status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00309725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309725.